Ensysce Biosciences (ENSC) Stock Price, News & Analysis

Company Overview

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF614, an extended-release oxycodone-derivative that releases clinically effective oxycodone; PF329 for pain with abuse protection; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD; and PF9001 to treat Opioid use disorder. The company was founded in 2003 and is based in La Jolla, California.

Key Stats

• Today's Range: $2.02 to $2.12
• 50-Day Range: $1.66 to $3.67
• 52-Week Range: $1.62 to $14.67
• Volume: 42,900 shs
• Average Volume: 945,159 shs
• Market Capitalization: $4.79 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Ensysce Biosciences Stock Analysis - MarketRank™

Ensysce Biosciences scored higher than 5% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Ensysce Biosciences.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Ensysce Biosciences are expected to decrease in the coming year, from ($8.33) to ($12.77) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Ensysce Biosciences is -0.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Ensysce Biosciences is -0.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Ensysce Biosciences has a P/B Ratio of 0.78. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

8.15% of the float of Ensysce Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Ensysce Biosciences has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Ensysce Biosciences has recently decreased by 71.54%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Ensysce Biosciences does not currently pay a dividend.

Dividend Growth

Ensysce Biosciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

8.15% of the float of Ensysce Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Ensysce Biosciences has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Ensysce Biosciences has recently decreased by 71.54%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 4 people have searched for ENSC on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Ensysce Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 7.90% of the stock of Ensysce Biosciences is held by insiders.

Percentage Held by Institutions

Only 5.63% of the stock of Ensysce Biosciences is held by institutions.

ENSC Stock Analysis - Frequently Asked Questions

How have ENSC shares performed this year?

Ensysce Biosciences' stock was trading at $8.14 at the beginning of the year. Since then, ENSC stock has decreased by 75.2% and is now trading at $2.02.
View the best growth stocks for 2025 here.

How were Ensysce Biosciences' earnings last quarter?

Ensysce Biosciences, Inc. (NASDAQ:ENSC) released its quarterly earnings data on Tuesday, May, 13th. The company reported ($1.39) earnings per share for the quarter, beating the consensus estimate of ($3.02) by $1.63. The firm earned $1.32 million during the quarter, compared to the consensus estimate of $0.65 million. Ensysce Biosciences had a negative net margin of 109.49% and a negative trailing twelve-month return on equity of 192.54%.

When did Ensysce Biosciences' stock split?

Ensysce Biosciences's stock reverse split on Friday, March 31st 2023. The 1-12 reverse split was announced on Friday, March 31st 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, March 31st 2023. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

Who are Ensysce Biosciences' major shareholders?

Ensysce Biosciences' top institutional shareholders include Murchinson Ltd. (5.90%) and Adage Capital Partners GP L.L.C. (3.15%).
View institutional ownership trends.

How do I buy shares of Ensysce Biosciences?

Shares of ENSC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Ensysce Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Ensysce Biosciences investors own include Predictive Oncology (POAI), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Abbott Laboratories (ABT), Meta Platforms (META), Insulet (PODD) and Broadcom (AVGO).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 6/21/2025
• Next Earnings (Estimated): 8/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ENSC
• CIK: 1716947
• Web: ensysce.com
• Phone: 858-263-4196
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($6.54)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$7.99 million
• Net Margins: -109.49%
• Pretax Margin: -109.49%
• Return on Equity: -192.54%
• Return on Assets: -121.77%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.50
• Quick Ratio: 2.50

Sales & Book Value

• Annual Sales: $5.21 million
• Price / Sales: 0.92
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.59 per share
• Price / Book: 0.78

Miscellaneous

• Outstanding Shares: 2,370,000
• Free Float: 2,184,000
• Market Cap: $4.79 million
• Optionable: Not Optionable
• Beta: 0.97